Readout of ~1K patients at ASCO GI 2025 demonstrates that Signatera™ positive patients treated with both chemotherapy and celecoxib had a 40% improvement in overall survival versus chemotherapy alone ...

Researchers from SWOG Cancer Research Network, a cancer clinical trials group funded by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), will share results of ...

Two potentially practice-changing studies published this month in the New England Journal of Medicine showcase the biostatistical expertise at the SWOG Statistics and Data Management Center (SDMC) ...

SWOG Clinical Trials Partnerships (SWOG CTP) has signed a collaborative research agreement with Novartis Pharmaceuticals Corporation to form a strategic alliance via our Preferred Partnership Program ...

This story was first published on Jan. 4 as a press release from the SWOG Cancer Research Network. Despite having access to health insurance, nearly three out of four patients with metastatic ...

Patient-reported outcomes may be associated with cancer outcomes. We evaluated clinically significant fatigue (CSF), overall survival, adverse events (AEs), and quality of life (QOL) during cancer ...

The SWOG S1011 randomized phase 3 trial found no significant improvement in disease-free or overall survival but a higher rate of grade 3-4 adverse events and an increased risk of death in the 90 days ...

Resistance Mechanisms to Anti–Epidermal Growth Factor Receptor Therapy in RAS/RAF Wild-Type Colorectal Cancer Vary by Regimen and Line of Therapy Clinical trials frequently include multiple end points ...

The SWOG S2302 Pragmatica-Lung trial, which broke new ground with its streamlined pragmatic design, unusually broad eligibility criteria, and reduced data collection, has quickly answered its primary ...

AUSTIN, Texas,--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, announced new data from the randomized, Phase III CALGB (Alliance) / SWOG 80702 ...